RxDoctor Payments Data

George Smith, MD

Family Medicine · Lineville, ALNPI 1285627828

Payments from drug & device makers

$2,659in general payments, 2019–2025

Across 136 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$670
  • Novo Nordisk$401
  • AbbVie$188
  • Novartis$182
  • Otsuka America Pharmaceutical, Inc.$164
  • Amgen$147
  • plus $907 from 16 others

What the payments were for

  • Food & beverage$2,54596%
  • Education$60%
  • Other$1074%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,659 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$253,326
Medicare patients
440
Services billed
4,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide231$243,039
EliquisApixaban488$231,674
FarxigaDapagliflozin Propanediol242$144,244
Humira(Cf) PenAdalimumab13$118,348
JardianceEmpagliflozin175$107,084
MounjaroTirzepatide81$86,679
Humira PenAdalimumab12$83,194
RybelsusSemaglutide55$65,760
LinzessLinaclotide101$60,741
XareltoRivaroxaban141$53,343
TrulicityDulaglutide42$46,440
TradjentaLinagliptin77$42,736
RexultiBrexpiprazole30$42,037
JanuviaSitagliptin Phosphate65$38,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$37,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$401$308,800286 claims
PfizerEliquis, Abrysvo$61$252,560555 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$670$189,952360 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$15$161,987276 claims
Lilly USA, LLCMounjaro, Trulicity$72$133,119123 claims
AbbVieLinzess$188$60,741101 claims
Johnson & JohnsonXarelto$12$53,343141 claims
GSKTrelegy Ellipta, Breo Ellipta$112$49,14170 claims
Otsuka America Pharmaceutical, Inc.Rexulti$164$42,03730 claims
NovartisEntresto$182$32,53386 claims
Avanir Pharmaceuticals, Inc.Nuedexta$39$30,55440 claims
AmgenProlia$147$22,76913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Lineville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →